Vcreate, Inc.
Menlo Park, CA
- UEI
- TDGANH2K4J93
- CAGE
- 8NSH5
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 1546 San Antonio St, Menlo Park, CA 94025, USA
- Website
- vcreate.io
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $0 |
| FY2024 | $355,000 |
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Concept sbir - t-cell receptors for treating pediatric acute myeloid leukemia | National Cancer Institute (NIH) | $355,000 |
Grant awards
Similar vendors
About the company
Vcreate, Inc. is a minority-owned, self-certified small disadvantaged business specializing in biomedical research and advanced immunotherapy technologies, with a specific focus on developing innovative T-cell receptor (TCR) based approaches for cancer treatment. Registered in SAM.gov since July 2020, the company operates as a for-profit corporate entity located in West Menlo Park, California, and has demonstrated expertise in developing cutting-edge therapeutic platforms for addressing complex medical challenges, particularly in oncology.
Through federal contract awards, Vcreate, Inc. has secured competitive contracts with civilian agencies, most notably the National Cancer Institute (NCI). The company's primary contract work involves conducting specialized research in pediatric cancer therapeutics, specifically developing T-cell receptors for treating pediatric acute myeloid leukemia. This $355,000 firm fixed price definitive contract was set aside for small businesses and represents a Phase I Small Business Technology Transfer (STTR) award aimed at demonstrating technical feasibility and proof-of-concept for innovative cancer treatment approaches. The contract highlights Vcreate's capability to secure competitive federal contracts in the biomedical research sector, with a focus on addressing critical needs in pediatric oncology.
Vcreate, Inc. has been particularly successful in obtaining federal grant awards from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships program. The company has received multiple grants totaling over $1.2 million, all focused on developing high-throughput platforms for discovering T-cell receptor-based immunotherapies for late-stage cancer patients. These grant awards include a Phase I grant of $256,000 to develop a high-throughput platform for screening TCRs against cancer antigens, and a subsequent Phase II cooperative agreement for $1,000,000 to further advance the platform's capabilities. The grants aim to generate data linking TCRs to cancer antigen targets and validate promising TCRs for specific and potent cancer cell killing. The research objectives include creating computational algorithms to predict TCR-MHC interactions and developing innovative screening technologies that could potentially transform cancer immunotherapy approaches.
Quick answers
Is Vcreate, Inc. registered in SAM.gov?
Yes. Vcreate, Inc.'s SAM.gov registration is active through December 15, 2026.
How much has Vcreate, Inc. received in federal contracts?
Federal contracts obligated $355,000 to Vcreate, Inc. in fiscal years 2023 through 2027.
What is Vcreate, Inc.'s most recent federal award?
Vcreate, Inc.'s most recent federal grant award is Sbir phase II: high throughput and antigen specific t-cell receptor discovery for solid tumor treatments (2406662), from National Science Foundation, on August 15, 2024.
On GovTribe
See Vcreate, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors